Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: An updated meta-analysis of individual patient data
Read the article: Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: An updated meta-analysis of individual patient data
Published 7 March 2017.
Watch the accompanying videoclip, summarizing the importance of the research.
Comment from author, Prof. Roberto Romero
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD/NIH), MI, USA

'The findings represent persuasive evidence that treatment with vaginal progesterone in women with a short cervix and a twin gestation reduces the frequency of preterm birth, neonatal complications such as respiratory distress syndrome, and importantly, neonatal death.'
Comment from UOG Editor-in-Chief, Prof. Basky Thilaganathan
London, UK

'To date, clinical practice and national recommendations to prevent preterm birth and reduce related adverse outcome in twin pregnancies vary significantly because of a lack of convincing scientific evidence and regional variation in the interpretation of said evidence. The findings of this individual patient data meta-analysis provides scientific evidence that treatment with vaginal progesterone in women with a short cervix and a twin pregnancy reduces the frequency of preterm birth and related serious adverse perinatal outcomes.